In addition to SeP and LECT2, these hepatokines and metabolic disorders are complexly intertwined; therefore, the measurement and activity of hepatokines may help to identify a deeper mechanism of accelerating metabolic disorders in patients with severe obesity. This evidence concerns the gene SELENOP and metabolic disease.